Evidence map›Paper›PMID 36421474›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Safety Assessment of 3S, 3'S Astaxanthin Derived from Metabolically Engineered

Sabrina Yeo Samuel, Hui-Min David Wang, Meng-Yuan Huang, Yu-Shen Cheng, Juine-Ruey Chen, Wen-Hsiung Li, Jui-Jen Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. High-Purity Bioactive Ingredient-3Antioxidants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sabrina Yeo SamuelTrade Wind Biotech Co., Ltd., Taipei 11574, Taiwan.
Hui-Min David WangGraduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung 40227, Taiwan.ORCID 0000-0002-4692-4917
Meng-Yuan HuangDepartment of Life Science, National Chung Hsing University, Taichung 40227, Taiwan.ORCID 0000-0002-3696-4827
Yu-Shen ChengDepartment of Chemical and Materials Engineering, National Yunlin University of Science and Technology, Yunlin 64002, Taiwan.ORCID 0000-0001-5394-8573
Juine-Ruey ChenRuenHuei Biopharmaceuticals Inc., Taipei 10050, Taiwan.
Wen-Hsiung LiBiodiversity Research Center, Academia Sinica, Taipei 11529, Taiwan.
Jui-Jen ChangGraduate Institute of Integrated Medicine, China Medical University, Taichung 40447, Taiwan.

Funding

Ministry of Science and Technology 109-2621-M-039-001Ministry of Science and Technology 109-2621-M-039-002Taipei City Government 1Z1100894
6 · The paper itself

Abstract

Previous reviews have already explored the safety and bioavailability of astaxanthin, as well as its beneficial effects on human body. The great commercial potential in a variety of industries, such as the pharmaceutical and health supplement industries, has led to a skyrocketing demand for natural astaxanthin. In this study, we have successfully optimized the astaxanthin yield up to 12.8 mg/g DCW in a probiotic yeast and purity to 97%. We also verified that it is the desired free-form 3S, 3'S configurational stereoisomer by NMR and FITR that can significantly increase the bioavailability of astaxanthin. In addition, we have proven that our extracted astaxanthin crystals have higher antioxidant capabilities compared with natural esterified astaxanthin from

Indexed as

3S3S′ astaxanthinantioxidantfood safetyKluyveromyces marxianusprobiotics

Identifiers

PMID36421474
PMCPMC9687027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.